Susquehanna International Group’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-240,190
| Closed | -$1.4M | – | 14077 |
|
|
2022
Q4 | $1.4M | Buy |
240,190
+202,781
| +542% | +$1.07M | ﹤0.01% | 5436 |
|
|
2022
Q3 | $251K | Buy |
+37,409
| New | +$227K | ﹤0.01% | 10268 |
|
|
2022
Q2 | – | Sell |
-15,476
| Closed | -$61.2K | – | 14399 |
|
|
2022
Q1 | $52K | Buy |
+15,476
| New | +$49.1K | ﹤0.01% | 12301 |
|
|
2021
Q4 | – | Sell |
-51,294
| Closed | -$171K | – | 14244 |
|
|
2021
Q3 | $168K | Sell |
51,294
-23,918
| -32% | -$83.8K | ﹤0.01% | 11686 |
|
|
2021
Q2 | $317K | Buy |
75,212
+62,709
| +502% | +$265K | ﹤0.01% | 10664 |
|
|
2021
Q1 | $62K | Sell |
12,503
-7,756
| -38% | -$62.7K | ﹤0.01% | 11993 |
|
|
2020
Q4 | $256K | Buy |
+20,259
| New | +$231K | ﹤0.01% | 9593 |
|
|
2020
Q2 | – | Sell |
-18,172
| Closed | -$161K | – | 11218 |
|
|
2020
Q1 | $161K | Buy |
18,172
+4,038
| +29% | +$39.8K | ﹤0.01% | 8928 |
|
|
2019
Q4 | $130K | Sell |
14,134
-18,732
| -57% | -$133K | ﹤0.01% | 9019 |
|
|
2019
Q3 | $193K | Buy |
32,866
+14,113
| +75% | +$150K | ﹤0.01% | 9128 |
|
|
2019
Q2 | $225K | Buy |
+18,753
| New | +$202K | ﹤0.01% | 8902 |
|
|
2019
Q1 | – | Sell |
-19,568
| Closed | -$288K | – | 10139 |
|
|
2018
Q4 | $246K | Buy |
+19,568
| New | +$270K | ﹤0.01% | 7377 |
|
|
2018
Q1 | – | Sell |
-52,232
| Closed | -$1.16M | – | 10437 |
|
|
2017
Q4 | $1.35M | Buy |
+52,232
| New | +$1.05M | ﹤0.01% | 4641 |
|
|
2017
Q1 | – | Sell |
-33,837
| Closed | -$406K | – | 10268 |
|
|
2016
Q4 | $348K | Buy |
+33,837
| New | +$309K | ﹤0.01% | 7699 |
|
|
2015
Q2 | – | Sell |
-32,421
| Closed | -$494K | – | 10579 |
|
|
2015
Q1 | $491K | Buy |
32,421
+19,283
| +147% | +$269K | ﹤0.01% | 7136 |
|
|
2014
Q4 | $175K | Buy |
+13,138
| New | +$170K | ﹤0.01% | 8918 |
|
|
2014
Q3 | – | Sell |
-12,102
| Closed | -$122K | – | 10084 |
|
|
2014
Q2 | $122K | Buy |
+12,102
| New | +$117K | ﹤0.01% | 9350 |
|
Susquehanna International Group's CNCE Position: Q1 2023 in Review
Susquehanna International Group sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2023, closing a stake of 240,190 shares — an estimated $1.4M sold.
Susquehanna International Group first reported a position in CNCE in Q2 2014 and held it in 17 quarters. The position peaked at $1.4M in Q4 2022. 0 funds tracked by Wall St. Rank hold CNCE as of Q1 2023.
- Susquehanna International Group reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
- Susquehanna International Group sold 240,190 Concert Pharmaceuticals, Inc. shares in Q1 2023, an estimated $1.4M.
- Susquehanna International Group first reported a position in Concert Pharmaceuticals, Inc. in Q2 2014 and held it in 17 quarters.
- Susquehanna International Group's Concert Pharmaceuticals, Inc. position peaked at $1.4M in Q4 2022.
- 0 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2023.
Based on Susquehanna International Group's 13F filing for Q1 2023, filed 16 May 2023.